Jason Luke, MD

Jason Luke, MD, associate director for clinical research and director of the Immunotherapy and Drug Development Center at Hillman Cancer Center, University of Pittsburgh.

Articles

Treatment Options for Relapsed Metastatic Cutaneous Melanoma

July 9th 2025

Panelists discuss expanding treatment options beyond frontline therapy for metastatic melanoma, emphasizing the use of targeted therapies, combination immunotherapies, and emerging modalities such as oncolytic virus and adoptive cell therapy while highlighting the balance between efficacy, toxicity, patient-centered outcomes, and practical challenges in clinical decision-making.

The Role of ctDNA in the Diagnosis and Management of Metastatic Melanoma

July 9th 2025

Panelists discuss the evolving role of circulating tumor DNA (ctDNA) in metastatic melanoma management, recognizing its potential as a minimal residual disease (MRD) marker and monitoring tool while emphasizing current limitations, investigational status, and the need for further research to define its clinical utility.

IL-6 Blockade and the Mitigation of ICI Toxicity

July 2nd 2025

Panelists discuss emerging strategies to reduce toxicity in dual immune checkpoint blockade for metastatic melanoma, focusing on promising early data with anti–IL-6 agents such as sarilumab. They acknowledge challenges around scalability, cost, and validation in broader populations and emphasize the importance of ongoing research and clinical trials to optimize tolerability without compromising efficacy.

Sequencing Therapy in BRAF V600-Mutant Metastatic Melanoma: The DREAMseq Trial

July 2nd 2025

Panelists discuss treatment sequencing for BRAF-mutated metastatic melanoma, highlighting evidence from the DREAMseq trial that supports starting with immunotherapy for better long-term survival while acknowledging clinical scenarios where rapid-response targeted therapy may be appropriate and emphasizing the need for flexibility based on patient condition and emerging data.

Choosing a Preferred Combination Immune Checkpoint Inhibitor (ICI) Regimen and Identifying Patients Appropriate for ICI Monotherapy

June 25th 2025

Panelists discuss frontline treatment preferences for metastatic melanoma, emphasizing the durability of combination immunotherapies like nivolumab plus ipilimumab, the emerging role of nivolumab plus relatlimab, and the importance of tailoring therapy based on disease characteristics, toxicity profiles, and individual patient factors.

Frontline Immunotherapy Treatment Options in Advanced or Metastatic Cutaneous Melanoma

June 25th 2025

Panelists discuss modern approaches to metastatic melanoma, focusing on recent advances in immunotherapy and cell therapies, individualized frontline treatment strategies, and evolving clinical data to guide clinicians in optimizing patient outcomes.

Dr Luke on the Role of IMA203 in Previously Treated Advanced Cutaneous Melanoma

June 6th 2025

Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors

April 20th 2023

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

Dr. Luke on the Importance of a Multidisciplinary Approach in Basal Cell Carcinoma

June 30th 2022

Jason Luke, MD, FACP, discusses the importance of a multidisciplinary approach in basal cell carcinoma.

Dr. Luke on Toxicities With Targeted Therapy Vs Immunotherapy in Melanoma

December 1st 2021

Jason J. Luke, MD, FACP, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma.

Dr. Luke on the Results of the Phase 3 KEYNOTE-716 Trial in Melanoma

September 19th 2021

Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.

Dr. Luke on Predictive Versus Prognostic Biomarkers in Melanoma

January 6th 2021

Jason J. Luke, MD, FACP, compares predictive and prognostic biomarkers in melanoma.

Dr. Luke the Role of Molecular Testing in Melanoma

November 24th 2020

Jason J. Luke, MD, FACP, discusses the role of molecular testing in melanoma.

Dr. Luke on the Role of Targeted Therapy in Melanoma

November 4th 2020

Jason J. Luke, MD, FACP, discusses the role of targeted therapy in melanoma.

Dr. Luke on the Importance of BRAF in Melanoma

October 28th 2020

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

Dr. Luke on the Clinical Trial Landscape for Melanoma

November 29th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma

Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma

November 10th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.

Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

October 28th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

Dr. Luke Discusses PD-1 Plus IDO Inhibitors in Melanoma

October 19th 2017

Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the combination approach of a PD-1 antibody plus an IDO inhibitor for patients with melanoma.